A study to evaluate the safety and effectiveness of empasiprubart and efgartigimod alfa in patients with generalized myasthenia gravis.

This study is being conducted to evaluate the safety and effectiveness of different treatment approaches for Myasthenia Gravis. This is a rare autoimmune disease where the body's immune system mistakenly attacks the connection between nerves and muscles, leading to muscle weakness. Specifically, this research focuses on a subtype called AChR-Ab Seropositive Generalized Myasthenia Gravis, which means the disease is present throughout the body and certain antibodies, known as acetylcholine receptor antibodies, can be detected in the blood.

The research involves the use of two medications: efgartigimod alfa and empasiprubart. Both of these are administered through an IV infusion, which is a method of delivering medication directly into a vein. Some participants will receive efgartigimod alfa alone, while others will receive empasiprubart as an additional treatment added to their current efgartigimod alfa therapy. This approach is intended for individuals who have experienced only a partial improvement in their symptoms while using the first medication.

During the study, participants will follow a specific treatment schedule to observe how the medications affect their condition and overall health. Monitoring will include checking vital signs and conducting an ECG, which is a test that records the electrical activity of the heart, to ensure the treatments are tolerated well. The study aims to observe changes in how much the disease impacts daily activities and the severity of muscle weakness over time.